Wednesday, May 20, 2026 | 10:16 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Natco Pharma Ltd Quarterly Results

Q3 FY25-26 Results Summary

Revenue

The revenue stands at ₹647.30 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 52.51 per cent from ₹1,363.00 crore. This corresponds to a year-on-year *(YoY) growth of 36.33 per cent.

Operating Profit

Operating Profit stands at ₹158.70 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 72.60 per cent from ₹579.20 crore. This corresponds to a year-on-year *(YoY) growth of 309.02 per cent.

PBDT

PBDT stands at ₹218.20 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 67.24 per cent from ₹666.10 crore. This corresponds to a year-on-year *(YoY) growth of 3.56 per cent.

Profit Before Tax

Profit Before Tax stands at ₹172.00 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 71.97 per cent from ₹613.70 crore. This corresponds to a year-on-year *(YoY) growth of 5.07 per cent.

Net Profit

Net Profit stands at ₹151.30 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 70.79 per cent from ₹517.90 crore. This represents a 14.27 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Natco Pharma Ltd Earnings

Data not available

Natco Pharma Ltd Earning Charts

Revenue from Operations

in ₹ cr

EBITDA

in ₹ cr

Profit before Tax

in ₹ cr

Net Profit

in ₹ cr

Natco Pharma Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Hold 1,110Edelweiss Securities24-Jul-2025
Hold 1,440Edelweiss Securities04-Oct-2024

Natco Pharma Ltd Financial Reports

Filter By:
Loading...

Natco Pharma Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 month3 month6 month1 Year
Natco Pharma2.69%-3.46%10.07%30.13%34.46%32.71%
Neuland Labs.1.24%1.67%13.73%24.38%2.33%51.79%
OneSource Speci.1.03%2.51%19.53%40.89%14.39%11.30%
Pfizer-2.46%-0.51%-3.19%-8.03%-6.76%-6.34%
ERIS Lifescience1.76%0.73%0.49%2.49%-16.77%-7.96%
Granules India-0.24%3.97%14.41%27.68%40.66%47.72%
Rubicon Research0.53%4.11%8.32%28.05%47.01%58.55%

Company Info

Company Information

Chairman / Executive Director / M D / Promoter : V C Nannapaneni

Vice Chairman & Chief Executive Officer : Rajeev Nannapaneni

ED / EVP : PSRK Prasad

ED / President : D Linga Rao

Independent Non Exe. Director : A D Murthy Chavali

Independent Non Exe. Director : Vijayabhaskar Dronadula

Independent Non Exe. Director : B. Lakshminarayana

Independent Non Exe. Director : Kantipudi Suma

Independent Non Exe. Director : Nitin Jain

Company Sec. & Compli. Officer : Chekuri Venkat Ramesh

Natco Pharma Ltd News

Data Not Available